[
    [
        {
            "time": "",
            "original_text": "200家国内药企排名公布，这些企业上榜（附名单）",
            "features": {
                "keywords": [
                    "药企",
                    "排名",
                    "榜单"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "200家国内药企排名公布，这些企业上榜（附名单）",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【云岭改革进行时】于传承中创新发展——混改一年看云南白药（下）",
            "features": {
                "keywords": [
                    "混改",
                    "云南白药",
                    "创新",
                    "发展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【云岭改革进行时】于传承中创新发展——混改一年看云南白药（下）",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|周报】推荐Q3业绩高增长板块（API、CXO、检测），关注新冠疫苗Q4进展",
            "features": {
                "keywords": [
                    "Q3业绩",
                    "高增长",
                    "API",
                    "CXO",
                    "检测",
                    "新冠疫苗",
                    "Q4进展"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商医药|周报】推荐Q3业绩高增长板块（API、CXO、检测），关注新冠疫苗Q4进展",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]